Jacobs Levy Equity Management, Inc Solid Biosciences Inc. Transaction History

Jacobs Levy Equity Management, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.69 - $2.46 $108,457 - $157,872	-64,176 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.38 - $3.77 $226,802 - $359,262	-95,295 Reduced 59.76%	64,176 $153,000
Q1 2021 May 17, 2021	SELL	$5.37 - $10.72 $821,454 - $1.64 Million	-152,971 Reduced 48.96%	159,471 $882,000
Q4 2020 Feb 16, 2021	BUY	$3.08 - $7.79 $428,064 - $1.08 Million	138,982 Added 80.12%	312,442 $2.37 Million
Q3 2020 Nov 16, 2020	BUY	$2.02 - $3.08 $131,053 - $199,824	64,878 Added 59.75%	173,460 $352,000
Q2 2020 Aug 17, 2020	BUY	$2.1 - $3.42 $165,001 - $268,716	78,572 Added 261.82%	108,582 $318,000
Q1 2020 May 15, 2020	BUY	$2.31 - $4.43 $69,323 - $132,944	30,010 New	30,010 $72,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $36.5M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.